

Mikhail Sergeevich Zastrozhin

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/4294150/mikhail-sergeevich-zastrozhin-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38

papers

709

citations

10

h-index

26

g-index

41

ext. papers

1,580

ext. citations

5.8

avg, IF

2.79

L-index

#	Paper	IF	Citations
38	Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. <i>The Lancet Global Health</i> , 2021 , 9, e144-e160	13.6	253
37	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020 , 396, 1250-1284	40	112
36	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021 , 397, 2337-2360	40	97
35	Hearing loss prevalence and years lived with disability, 1990-2019: findings from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021 , 397, 996-1009	40	82
34	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet, The</i> , 2020 , 396, 693-724 ⁴⁰	40	32
33	The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2016 , 9, 89-95	2.1	16
32	Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019 , 97, 781-785	2.4	14
31	Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. <i>Drug Metabolism and Personalized Therapy</i> , 2017 , 32, 129-136	2	14
30	Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. <i>Human Psychopharmacology</i> , 2018 , 33, e2677	2.3	13
29	Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 113-119	2.1	11
28	Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. <i>Lancet HIV,the</i> , 2021 , 8, e363-e375	7.8	10
27	Pharmacogenetics of alcohol addiction: current perspectives. <i>The Application of Clinical Genetics</i> , 2019 , 12, 131-140	3.1	9
26	Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 209-215	2.1	8
25	The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 1-5	2.1	7
24	Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. <i>Gene</i> , 2020 , 739, 144513	3.8	6
23	Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome. <i>Hospital Pharmacy</i> , 2021 , 56, 592-596	1.1	5
22	Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 187-194	2	5

21	Effects of polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020 , 21, 111-123	2.6	3
20	Anxiety and Depression Among Transgender People: Findings from a Cross-Sectional Online Survey in Russia. <i>LGBT Health</i> , 2021 , 8, 412-419	4.9	3
19	The effect of and gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy. <i>Drug Metabolism and Personalized Therapy</i> , 2021 ,	2	2
18	CYP3A subfamily activity affects the equilibrium concentration of Phenazepam in patients with anxiety disorders and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020 , 21, 449-457	2.6	1
17	Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	1
16	Pharmacogenetic evaluation of adverse events risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms 2017 , 1, 18-26		1
15	Pharmacodynamic gene polymorphism and adverse drug reactions then applying antipsychotic drugs 2017 , 1, 5-12		1
14	Cybersex addiction in a gay man: a case report. <i>Journal of Addictive Diseases</i> , 2021 , 39, 425-431	1.7	1
13	CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 200-208	0.9	1
12	Priming Future Cultural Identities in Self-Defining Future Projections: Findings of a Pilot Online Cross-Sectional Study. <i>Cultural-Historical Psychology</i> , 2021 , 17, 104-114	0.9	0
11	Olanzapine-Associated Rhabdomyolysis: A Case Report. <i>Cureus</i> , 2021 , 13, e12568	1.2	0
10	The effect of brain neurotrophic factor gene polymorphism on the effectiveness of therapeutic and rehabilitation measures in patients with psychostimulant dependence. <i>Neurology Bulletin</i> , 2021 , LIII, 26-32	0.2	0
9	The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. <i>Bulletin of Siberian Medicine</i> , 2020 , 18, 119-126	0.4	
8	Assessment of the impact of the steady state level of microRNA hsa-miR-370-3p concentration on the efficacy and safety profile of fluvoxamine in patients with depressive disorders disorder comorbid with alcohol use disorders. <i>Vestnik Nevrologii, Psihiatrii I Nejrohirurgii</i> , 2020 , 37-46	0.1	
7	Personalized approach to the administration of haloperidol in patients with acute alcoholic hallucinatie (literature review). <i>Vestnik Nevrologii, Psihiatrii I Nejrohirurgii</i> , 2021 , 628-638	0.1	
6	Effect of combination antihypertensive therapy, including renin-angiotensin-aldosterone system inhibitors, on oxidative stress and arterial remodeling in hypertensive patients with heart failure with preserved ejection fraction. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4158	1.3	
5	A case of olanzapine-associated rhabdomyolysis. <i>BJPsych Open</i> , 2021 , 7, S53-S53	5	
4	Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder. <i>Bulletin of Siberian Medicine</i> , 2021 , 19, 73-79	0.4	

- 3 The effect of and gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy.. *Drug Metabolism and Personalized Therapy*, **2021**, 37, 27-34 2
- 2 Epidemiology of simultaneous narcological and mental disorders in adolescence. *Vestnik Nevrologii, Psihiatrii I Nejrohirurgii*, **2021**, 783-799 0.1
- 1 Meta-analysis of pharmacogenetic decision support systems used in psychiatry. *Vestnik Nevrologii, Psihiatrii I Nejrohirurgii*, **2021**, 860-869 0.1